Compare GSK plc (GSK) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Northrop Grumman Corporation — how do they compare? GSK plc trades at $52.81 (market cap $101.34B), while Northrop Grumman Corporation trades at $524.06 (market cap $74.60B). The key difference: GSK plc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | NOC | |
|---|---|---|
Market Cap | $101.34B | $74.60B |
Sector | Health | Industrials |
52-Week High | $61.18 | $768.02 |
52-Week Low | $36.20 | $496.02 |
Enterprise Value | $121.95B | $88.82B |
Dividend Yield | 3.49% | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Northrop Grumman (NOC) trades at $524.32, down 0.82% with a bearish technical signal. The company shows strong fundamentals with consistent earnings beats, a 10.8% net income margin, and a $95.6 billion backlog. Recent news highlights expansion in missile defense and space systems, supported by increased defense spending expectations. Technical indicators show the stock near support at $522 with oversold RSI conditions suggesting potential near-term stabilization.
The investment case remains positive with analyst consensus at $655 target (25% upside) and strong institutional support. Key risks include political uncertainty around defense budgets and execution challenges. The combination of solid fundamentals, earnings momentum, and strategic positioning in defense and aerospace supports a constructive outlook despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
